News

Learn how and why East Indian Sandalwood Oil (EISO) is making international headlines as a unique, non-substitutable botanical drug candidate.

Santalis Pharmaceuticals Enrolls First U.S. Subject Into a Phase 2 Clinical Study of Mild to Moderate Atopic Dermatitis

Posted on

SAN ANTONIO – (MEDIA) – Santalis Pharmaceuticals has announced enrollment of the first U.S. subject into a multi-center, placebo-controlled, double-blind, safety, tolerability and efficacy study of a unique 5% Sandalwood Album Oil (SAO), also known as East Indian Sandalwood Oil (EISO), cream formulation for the treatment of atopic dermatitis (AD), also known as eczema. Subjects will be 18 to 65 […]Read More Santalis Pharmaceuticals Enrolls First U.S. Subject Into a Phase 2 Clinical Study of Mild to Moderate Atopic Dermatitis

Santalis Pharmaceuticals Announces Issuance of an Australian Patent Covering the Use of Sandalwood Oil to Treat Cancers

Posted on

SAN ANTONIO – (MEDIA) – Santalis Pharmaceuticals, Inc. announced today the granting by the Australian Patent Office of patent No. 2011223758 containing sixteen claims covering the use of sandalwood oil compositions to treat a variety of cancers including leukemia and solid tumors, such as bladder cancer, and others. According to Dr. Paul Castella, CEO of Santalis Pharmaceuticals, “We’re very pleased […]Read More Santalis Pharmaceuticals Announces Issuance of an Australian Patent Covering the Use of Sandalwood Oil to Treat Cancers

San Antonio Biotech Firm Readies Skin Treatment for Distribution

Posted on

ViroXis Corp. has signed a licensing agreement with a global pharmaceutical company to market over-the-counter products containing sandalwood oil. The San Antonio-based biotech company has been working to develop a treatment for skin warts using byproducts of the East Indian Sandalwood tree. The company recently wrapped up a Phase 2 clinical study of its treatment for the Human Papilloma Virus […]Read More San Antonio Biotech Firm Readies Skin Treatment for Distribution